Join
Live feed
·
PRReleasevia Quantisnow
Werewolf Therapeutics Inc. logo

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
HOWL· Werewolf Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HOWL (Werewolf Therapeutics Inc.) and more on Quantisnow.